Literature DB >> 9851811

Association between polymorphisms in the fibrinogen alpha- and beta-genes on the post-trauma fibrinogen increase.

C Ferrer-Antunes1, M P de Maat, A Palmeiro, J Pimentel, V Fernandes.   

Abstract

Fibrinogen is an acute phase reactant, and therefore its plasma levels increase after severe injury. Polymorphisms in the fibrinogen alpha and beta genes have been found to be associated with plasma levels of fibrinogen, and it has also been suggested that they are associated with the fibrinogen increase in acute phase situations. In forty-five consecutive patients admitted to the Intensive Care Unit after acute cranial or thoracic trauma, we investigated the influence of four polymorphisms at the fibrinogen loci (-455G/A and BclI (beta gene), TaqI and T/A312 (alpha gene)) on the post-trauma increase of the fibrinogen levels. At admission, fibrinogen levels were comparable in the patients with the different genotypes for the four polymorphisms studied. However, patients carrying the -455A allele of the -455G/A polymorphism had a significantly wider variation and higher peak levels of fibrinogen, during their stay at the intensive care unit, than did the -455GA homozygotes (5.1 g/l (SD 1.3) and 5.9 g/l (SD 1.0), respectively, p<0.05). Such difference was not found for the other studied polymorphisms. The present study suggests that the increase of fibrinogen level in acute phase situations like severe trauma is associated with the beta-gene -455G/A polymorphism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851811     DOI: 10.1016/s0049-3848(98)00143-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

Review 1.  [Gene polymorphism in intensive care patients. Is the course of disease predetermined?].

Authors:  S Ziegeler; S Kleinschmidt; C D Collard
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

2.  Quantile-specific heritability of plasma fibrinogen concentrations.

Authors:  Paul T Williams
Journal:  PLoS One       Date:  2022-01-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.